Shortlisted: Innovation in ManufactureRadio Ligand Therapy for Cancer Treatment Novartis successfully development formulation for clinical studies and commercial manufacturing of Pluvicto for treatment of Cancer patients. PluvictoTM (lutetium Lu 177 vipivotide tetraxetan) is indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have already been treated
Search:
This site uses cookies. By browsing this website you agree to our use of cookies. Find out more
Registration is now open!
Claim your free ticket
Entry and access to all content is free
Plus, claim a Certificate of Attendance for your CPD record